Jump to content

Drilldown: Medicines

Choose a table:


Medicines > legal : Currently legal in most jurisdictions with thujone limits or [[USLegal:Prescription only|Rx-only]] in US or None

Use the filters below to narrow your results.

generic:
 
brand:
uses:
None (396) · '"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' (6) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (5) · '"`UNIQ--vote-00000006-QINU`"' (4) · '"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (3) · '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (3) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (2) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (2) · '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' (2)
starting dose:
None (411) · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (2)
preparations:
None (397) · 10 mg, 20 mg, 40 mg, 80 mg tablets (2) · 5, 10 mg tablets (2) · 5, 10, 20, 40 mg tablets (2)
fda max:
None (413) · Indication-specific (6) · 80 mg/d (5) · 10 mg/d (3) · 4 g/d (3) · 40 mg/d (3) · 100 mg/d (2) · 5 mg/d (2) · 600 mg/d (2) · No fixed maximum; titrated to TSH target (2) · TID per eye (2) · Titrated to glucose; no fixed ceiling (2)
routes:
None (397) · Oral (122) · IV (30) · IM (13) · topical (11) · Subcutaneous (6) · Topical ophthalmic (5) · intranasal (4) · ophthalmic (4) · rectal (4) · vaginal (4) · transdermal (3)
onset:
None (412) · Hours (11) · 1-2 hours (3) · 30-60 minutes (3) · LDL lowering at 2 weeks, max by 4 weeks (3) · BP and symptomatic LUTS improvement within 1-2 weeks (2) · BP effect within 1-2 weeks (2) · Clinical improvement within 24-72 hours (2) · Motor improvement over days at therapeutic dose (2) · Postprandial glucose effect within days; HbA1c by 12 weeks (2)
duration:
None (411) · 24 hours (32) · 4-6 hours (7) · 12 hours (4) · 6-8 hours (4) · 8-12 hours (4) · 12-24 hours (3) · Hours per application (3) · N/A (2) · Steady-state at 4-6 weeks (2)
halflife:
None (412)
bioavailability:
None (413) · ~100% (oral)'"`UNIQ--ref-0000001C-QINU`"' (2) · ~100% from subcutaneous depot (2)
pregnancy:
None (424) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (7) · Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (3) · Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Avoid where possible; class concerns as for other loop diuretics.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Generally considered safe in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Limited human data; rarely indicated in pregnancy given the patient population.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Limited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2)
legal: (Click arrow to add another value)

Showing below up to 250 results in range #1 to #250.

View (previous 250 | ) (20 | 50 | 100 | 250 | 500)

B

C

D

E

F


View (previous 250 | ) (20 | 50 | 100 | 250 | 500)